Within the context of breast cancers, ER+ cancers exhibit less abundant immune infiltrates and fewer somatic mutations with concomitant reduced potential for tumor neo-antigens, compared to HER2+ and triple negative breast cancers (TNBC) [7, 8]. The gene discussed is ESR1; the disease is breast cancer.